Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. - Wikidata - wikimedia - TriplyDB

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

http://www.wikidata.org/entity/Q33665758

about

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?VEGFR-2 expression in human melanoma: revised assessment.Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).From melanocyte to metastatic malignant melanoma G-protein-coupled receptor-2-interacting protein-1 is required for endothelial cell directional migration and tumor angiogenesis via cortactin-dependent lamellipodia formation Relationships between VEGF protein expression and pathological characteristics of diffuse large B cell lymphoma: a meta-analysis.Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin Angiogenesis and melanoma - from basic science to clinical trials.Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells Serum markers in early-stage and locally advanced melanoma.Ultrafiltration and Microarray for Detection of Microbial Source Tracking Marker and Pathogen Genes in Riverine and Marine Systems Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.Receptor tyrosine kinases and their activation in melanoma.Molecular biology of normal melanocytes and melanoma cells.Inhibition of angiogenesis for the treatment of metastatic melanoma.Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma - implications for therapeutic strategies and targeted therapies.Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications.The WNT-less wonder: WNT-independent β-catenin signaling.Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades.Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.Emerging growth factor receptor antagonists for the treatment of advanced melanoma.Microvessel density and VEGF, HIF-1α expression in primary oral melanoma: correlation with prognosis.VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells.Interval sentinel lymph nodes in melanoma: a digital pathology analysis of Ki67 expression and microvascular density.Toxicity and Immunogenicity in Murine Melanoma following Exposure to Physical Plasma-Derived Oxidants.Discovery of potential biomarkers in human melanoma cells with different metastatic potential by metabolic and lipidomic profiling.The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas.Tyrosine phosphorylation modulates the vascular responses of mesenteric arteries from human colorectal tumors.Metabolic risk factors and skin cancer in the Metabolic Syndrome and Cancer Project (Me-Can).Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis--correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met.An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel.Melanoma treatment in review.

P2860

Q26781098-4026C977-CEAB-4729-B0DB-F522EF14EDD6 Q28535159-BB9DEA50-7AE9-4DB5-BE25-2DF7EB3F971D Q29994573-57A50990-8607-4695-874D-0E539398A4C5 Q30423356-9CE08565-06B6-4B2E-8FC3-9890182E4AE9 Q33274369-5D91287E-7A94-4162-BC4F-83E7C5424365 Q33560677-A7CF4496-B95D-437C-9D34-3B37BCFF2C93 Q34000700-6ACE4684-15D3-4B57-BCB6-EDE35F1FD975 Q34169935-F1F627C6-F930-4F9B-AB0D-6AA93C34AE97 Q34972813-7F28C60D-FA9C-46A6-A5FC-08922CD48F41 Q35184465-622EF3EA-665B-497C-99A0-EF0B3543B44B Q35377689-430FCA3A-DAB6-4A54-881F-42E227386038 Q35380959-E4F2513A-D32D-4BDB-A209-393890752F0A Q35845352-6BD95CCC-1E7B-4F00-B88C-C3065FAB5FDD Q35949539-8B415EB0-B707-4802-9CC8-BCCC3E0A074A Q36188833-2DB92581-8927-4590-A019-11D558A216CA Q36352802-1ECFACC8-B8D2-4C82-8112-FA19DBC11A67 Q36631302-497B009E-82DD-4121-AFB4-D5DDFAF79018 Q36825455-21AB56FD-2F5F-421D-883B-EC1B5B272C1B Q37257170-CD5FEAD1-8492-4EE7-A034-FAE3AFA7B50F Q37841746-2709948D-AF3A-4895-879B-5DC0090B12B3 Q38092784-5C07B798-59DA-4973-A833-60958CD97882 Q38134302-5E3C65EE-A6F7-4AD1-9BD3-6FC4742A3014 Q38186064-96192467-73E4-4F52-BF4F-FE0326F5E0BE Q38196881-696844AF-C65E-4B2F-8655-25C84ECDA763 Q38867422-3E2773BD-F2D3-470A-B6A7-F811E80F030E Q39181848-ED83F785-4004-4A03-B3DA-C96084E7A275 Q39281703-748A34B9-8AE8-47E1-A8CC-0639B7F52D3E Q39340696-386838A9-B2FF-49A3-A8AA-BA1CA0206D54 Q39493116-19BFBFF5-5C95-40F5-B511-476CA6FB2B98 Q39787455-F18F58B2-E9C4-415C-80C3-BF1C42AF4811 Q40305491-5B92D837-5738-4CC0-8260-A71F97BFED50 Q41067821-C177AFCD-06C9-493F-9015-DA8E6419DF13 Q41458701-7842FE8A-9CAB-440E-BD94-71667091BC37 Q42511450-78050078-FF72-445B-921D-D6AC01ADE524 Q42864506-0EA3B9B7-8DD8-42A4-89D2-16B5055A344F Q45297206-06CBE681-DB4F-48F1-9BB5-3AF835083AF2 Q45570735-22EA6D08-B995-4E46-A212-2BD03C1A3B85 Q51746622-1D604BC6-1C4B-4126-BF17-9DE5E5B3EC04 Q55217220-D0D2411F-EF40-47B5-AFDD-6D0038EAA27E

P2860

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.

http://www.wikidata.org/entity/Q33665758

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Quantitative expression of VEG ...... n melanoma tissue microarrays.

@ast

Quantitative expression of VEG ...... n melanoma tissue microarrays.

@en

type

label

Quantitative expression of VEG ...... n melanoma tissue microarrays.

@ast

Quantitative expression of VEG ...... n melanoma tissue microarrays.

@en

prefLabel

Quantitative expression of VEG ...... n melanoma tissue microarrays.

@ast

Quantitative expression of VEG ...... n melanoma tissue microarrays.

@en

P1433

Q33665758-5C1624DB-2F7E-4B4D-8222-FA82563F69C8

P1476

Q33665758-6E93FDBC-5E85-43E6-AB48-E59CFDB36CB7

P2093

Q33665758-28468A50-0AB8-4788-B4A7-EC6EB7B1A681

Q33665758-2B4A6F01-585F-4BCA-90B4-915A840F2C1E

Q33665758-81DA3F6C-EBC9-4771-AB82-50E92CEAC1BF

Q33665758-AB57B069-7AE1-46E5-BB06-6BC02ECF7F96

Q33665758-C914DE15-EAC1-4EC8-8FA6-514D656B0090

Q33665758-D9DF8206-B855-4DDC-BE51-311E6AC67060

Q33665758-D9EF086E-22A5-4511-A9D3-A78B726A863B

P2860

Q33665758-0372F755-E4C0-4953-B01B-83CF91D38DC6

Q33665758-0810EFFA-1A59-4C68-A2E4-4B1BBF00BE50

Q33665758-13540200-E4EC-44F4-8A19-C52E112F53A5

Q33665758-14184B69-D78B-47DE-ADA9-4CBB4E21D82A

Q33665758-29B35A24-335E-4D0A-8D72-BF1CAA60BEB6

Q33665758-2B75D0F4-EB34-415B-9948-A934A2A09FE6

Q33665758-4D3502FF-089E-4E84-A4EE-6E3CFB9D7CB9

Q33665758-6429BBFC-22A5-40AE-8193-CA91EBAF7864

Q33665758-80A372D0-82F4-4E36-B6C1-8BF8F8A5162D

Q33665758-849E95AB-038D-4CB7-B524-18CFD68E987A

P304

Q33665758-A808FE23-3141-4CE6-81B3-2EAC4165A294

P31

Q33665758-86424DDD-1772-4E98-A74A-8B42555E9CCA

P356

Q33665758-64A1450F-288F-4C25-BD57-2182374AAE5D

P407

Q33665758-92109623-ABC9-48DD-8C08-B09FDDB07B0F

P433

Q33665758-4156ED58-7953-408A-B915-E2120B9DC062

P478

Q33665758-206C6232-45DA-48BB-A340-78DEF43A6797

P50

Q33665758-5DD54F59-A178-4252-909C-2C9140902E71

P577

Q33665758-9AA2FB47-412C-41AF-8731-18CB395B8951

P5875

Q33665758-A18A6134-1C31-4514-841C-1ED7751DC51C

P698

Q33665758-8548A2FB-A6AC-4FEF-9C83-E4D5B294B4EE

P932

Q33665758-ADD7AFA5-FD79-48D6-B7BD-02F4CC2666EE

P356

J.HUMPATH.2009.08.016

P1433

Human Pathology

P1476

Quantitative expression of VEG ...... n melanoma tissue microarrays.

@en

P2093

David L Rimm

http://www.w3.org/2001/XMLSchema#string

Harriet M Kluger

http://www.w3.org/2001/XMLSchema#string

Janice M Mehnert

http://www.w3.org/2001/XMLSchema#string

Lucia Jilaveanu

http://www.w3.org/2001/XMLSchema#string

Mary M McCarthy

http://www.w3.org/2001/XMLSchema#string

Robert L Camp

http://www.w3.org/2001/XMLSchema#string

Saadia Aziz

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2008

The biology of VEGF and its receptors

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.

Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.

A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful?

Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.

Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.

Lessons from phase III clinical trials on anti-VEGF therapy for cancer.

P304

375-384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.HUMPATH.2009.08.016

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40682775

http://www.w3.org/2001/XMLSchema#string

P698

20004943

http://www.w3.org/2001/XMLSchema#string

P932

2824079

http://www.w3.org/2001/XMLSchema#string